Diadem srl, perusahaan sing ngembangake tes adhedhasar getih kanggo prediksi awal lan diagnosis penyakit Alzheimer (AD), dina iki ngumumake manawa nampilake data ing Konferensi Internasional AD/PD™ 2022 babagan Penyakit Alzheimer lan Parkinson (AD/PD22) sing nuduhake manawa tes getih AlzoSure® Konfirmasi anyar bisa ngenali pasien kanthi penyakit Alzheimer. Presentasi, "Tes Berbasis Darah Non-Invasif Pertama kanggo Diagnosis Penyakit Alzheimer lan Demensia Liyane," diwenehake dening kepala eksekutif Diadem Paul Kinnon ing konferensi ing Barcelona, Spanyol tanggal 19 Maret 2022.
AlzoSure® Confirm wis dikembangake ing platform teknologi sing padha karo AlzoSure® Predict, tes getih prognostik Diadem sing bisa prédhiksi kanthi akurat apa individu sing ngalami owah-owahan kognitif awal bakal maju menyang penyakit Alzheimer nganti nem taun sadurunge kondisi kasebut diwujudake kanthi lengkap. AlzoSure® Predict wis ditetepake minangka Piranti Terobosan dening Administrasi Pangan & Narkoba AS lan bubar entuk tandha CE-IVD supaya bisa dipasarake ing Inggris lan Uni Eropa.
Assay anyar adhedhasar biomarker integratif U-p53AZ sing padha-varian konformasi p53-sing wis digandhengake karo patogenesis AD ing luwih saka 400 studi, kanthi interaksi sing didokumentasikake karo amyloid, tau lan faktor liyane sing ana gandhengane karo kemajuan pasien. kanggo AD. Teknologi paten Diadem wis dikembangake nggunakake platform U-p53AZ.
Ing panliten sing disajikake ing AD / PD22, peneliti Diadem nggunakake subset conto saka database longitudinal meh 500 pasien sing nuduhake macem-macem tahap penurunan kognitif kanggo neliti urutan lengkap modifikasi pasca-translasi (PTM) saka U-p53AZ sajrone kursus kasebut. saka continuum sing culminates ing penyakit Alzheimer. Dheweke nemokake manawa "sidik jari" PTM tartamtu, utawa tanda tangan, minangka karakteristik saka macem-macem tahapan kemajuan menyang AD. AlzoSure® Confirm nggunakake tandha PTM sing menehi ciri penyakit Alzheimer lengkap kanggo nyedhiyakake tes biomarker adhedhasar getih sing duweni potensi bisa diagnosa AD. Ing data validasi klinis awal Diadem sing ditampilake ing AD / PD22, tandha PTM iki bisa ndeteksi pasien AD lan mbedakake saka pasien karo demensia liyane.
"Ing Diadem, kita setya ngembangaken tes getih prognostik lan diagnostik sing bisa diakses kanthi tepat sing bisa ngenali kanthi tepat individu sing duwe penyakit Alzheimer utawa sing bakal maju menyang AD ing taun-taun sing bakal teka," ujare Pak Kinnon. "Tes getih prognostik AlzoSure® Predict kita wis divalidasi ing studi klinis longitudinal gedhe lan bakal kasedhiya ing EU ing pungkasan taun iki. Kita uga bungah banget babagan tes Konfirmasi AlzoSure® anyar, sing duweni potensi kanggo diagnosa penyakit Alzheimer kanthi akurat lan khusus kanthi nggunakake tes getih sing prasaja. Kurang diagnosis pas wektune, akurat lan terjangkau wis ngalangi kemajuan kanggo ngembangake pilihan perawatan sing luwih efektif kanggo pasien AD, lan kita ngarep-arep bisa kerja bareng karo macem-macem mitra kanggo ngasilake lan nglaporake data konfirmasi liyane ing AlzoSure® Confirm.
APA sing kudu dijupuk saka ARTIKEL INI:
- In the study presented at AD/PD22, Diadem researchers used a subset of samples from a longitudinal database of almost 500 patients exhibiting different stages of cognitive decline to investigate the full sequence of post-translational modifications (PTMs) of U-p53AZ over the course of the continuum that culminates in Alzheimer’s disease.
- Diadem srl, a company developing blood-based tests for the early prediction and diagnosis of Alzheimer’s disease (AD), today announced that it presented data at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD22) showing that its new AlzoSure® Confirm blood test can accurately identify patients with Alzheimer’s disease.
- AlzoSure® Confirm has been developed on the same technology platform that underlies AlzoSure® Predict, Diadem’s prognostic blood test that can accurately predict whether or not an individual with early cognitive changes will progress to Alzheimer’s disease up to six years before the condition is fully manifested.
